Ed Holson is the director of the medicinal chemistry group in the Stanley Center for Psychiatric Research and a director of chemistry in the Chemical Biology Platform at the Broad Institute. In February 2008, Holson joined the medicinal chemistry group at the Stanley Center to design and implement strategies toward developing novel therapies in central nervous system related disorders including schizophrenia, bipolar disorder, and cognitive impairment. These strategies include the rational design and development of novel, potent and highly selective small molecules suitable for clinical development. His group is interested in a range of biology including epigenetics, G-protein coupled receptors, kinases, and protein-protein interactions.
Prior to joining the Stanley Center, Holson worked for Infinity Pharmaceuticals and Merck & Co. in a variety of roles in medicinal chemistry and pharmaceutical development. Holson received his Ph.D. in chemistry from the University of Michigan where he worked with William R. Roush on developing novel methods for the synthesis of complex natural products.